DCAL vs KREBSBIO: Stock Comparison

DISHMAN CARBO AMCIS vs KREBS BIOCHEMICALS & INDUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

DISHMAN CARBO AMCIS is the larger company by market capitalisation. DISHMAN CARBO AMCIS shows faster revenue growth, a higher ROCE and a higher net margin, while KREBS BIOCHEMICALS & IND shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

DCAL leads 4; KREBSBIO leads 6 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

DCALKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹2,723 Cr
₹121 Cr
P/E RatioKREBSBIO has the lower reading
172.04x
0x
P/B RatioKREBSBIO has the lower reading
0.42x
0x
EPSKREBSBIO has the higher reading
₹-1.53
₹-1.15
Book ValueContext only
₹425.87
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
DCAL is the larger company
₹2,723 Cr vs ₹121 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 172.04x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 0.42x
EPS
KREBSBIO has higher earnings per share
₹-1.15 vs ₹-1.53
Revenue Growth (TTM YoY)
DCAL has faster revenue growth
18.9% vs 11.6%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -49.5%
Qtr Sales Growth
KREBSBIO has stronger quarterly sales growth
-70.57% vs -91.58%
Qtr Profit Growth
KREBSBIO has stronger quarterly profit growth
85.33% vs 58.69%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDCALKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDCALKREBSBIO
Live Price₹174.38₹55.95
Day Change-1.47%2.66%
Volume1.23 L5,830
52-Week High₹321.95₹82.49
52-Week Low₹128.5₹38.33
Distance from 52W High-45.84%-32.17%

Valuation

MetricDCALKREBSBIO
Market Cap₹2,723 Cr₹121 Cr
P/E Ratio172.04x0x
P/B Ratio0.42x0x
EPS₹-1.53₹-1.15
Book Value₹425.87
Dividend Yield0%0%

Growth

MetricDCALKREBSBIO
Revenue Growth (TTM YoY)18.9%11.6%
EPS Growth (TTM YoY)-49.5%0%
Qtr Sales Growth-91.58%-70.57%
Qtr Profit Growth58.69%85.33%

Profitability & Leverage

MetricDCALKREBSBIO
ROE1.46%
ROCE1.52%-15.89%
Net Margin2.51%-71.35%
Operating Margin9.52%-41.49%
Debt to Equity0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDCALKREBSBIO
Promoter Holding59.32%72.74%
FII Holding6.86% 0.59 pp0.5%
DII Holding2.07% 0.44 pp0%
Public Holding31.75% 0.15 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DISHMAN CARBO AMCIS and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.